What is PTCT's P/E ratio?

PTC THERAPEUTICS INC (PTCT) currently trades at a P/E ratio of 369.82.

PTC THERAPEUTICS INC reports a Return on Equity (ROE) of 103.47%.

What is PTCT's dividend yield?

PTC THERAPEUTICS INC offers a dividend yield of 0.00%.

What is PTCT's Deepscope Quality Score?

Deepscope rates PTCT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PTCT?

Deepscope's AI Timing Score for PTCT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PTCT belong to?

PTC THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

PTCT (NASDAQ) 株価分析 | PTC THERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-09 | FS: 2026-03-31)

PTCT

PTC THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 94

USD 73.68

2.81 (3.97%) Day Change

Watchlist Portfolio Compare Chart

369.82

P/E

-1.69

D/E

103.5%

ROE

-6.5%

ROA

0.00%

Div Yield

-3.70

PEG

PTC THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 73.68 Price 2.81 (3.97%) Day Change	NEWS SCORE: 94

PTCT, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/Eが高い。割高銘柄。
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Deepscope 分析

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	1650
Magic Formula Rank by ROE	1650
Magic Formula Rank by ROIC	1646
Price	73.68
PBV / Sector	-32.57 / 4.71
Earning Per Share	-2.34

PE / Sector	369.82 / 17.58
PEG or PE/Growth / Sector	-3.70 / 0.53
Average 1M Daily Value	77.35 M
Average 1W Daily Value	88.96 M

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-22.58 / 468.85
NPM Average (%) / Sector	-34.99 / -1,531.69
NPM Change Average (%) / Sector	-98.48 / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-6.51 / 31.69
ROA Average (%) / Sector	-14.04 / -353.18
ROA Change Average (%) / Sector	-93.12 / 5,214.65
ROE (%) / Sector	103.47 / 10.58 GREAT
ROE Average (%) / Sector	8.34 / 27.64
ROE Change Average (%) / Sector	-336.33 / 2,048.88
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 3.68

登録情報

Analyze Date	2026-06-10 09:43:40
Symbol	PTCT
Name	PTC THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	82.95 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,878.62 / 8,889.42

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059

Phone: 908 222 7000

Website: https://www.ptcbio.com

Employees: 991

Sector: Healthcare >> Biotechnology

Description: PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.